Business
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used to dateTopline data reported from the Phase II COVALENT-112 clinical trial of icovamenib in type 1 diabetes (“T1D”), supporting proposed mechanism of actionFirst patients dosed in the Phase II COVALENT-211 and COVALENT-212 clinical trials of icovamenib in type 2 diabetes (“T2D”); both trials are on trac
About this update from Biomea Fusion, Inc.
[{"type":"image","alt":"Biomea Fusion, Inc.","displaySize":"","headline":null,"caption":"Biomea Fusion, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/23ef33094735e204421f6d8274b615e3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HeFYZc6XS1ctfZIAnZmxfw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMg--/https://media.zenfs.com/en/globenewswire.com/23ef33094735e204421f6d8274b615e3","width":300,"height":80},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/HeFYZc6XS1ctfZIAnZmxfw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMg--/https://media.zenfs.com/en/globenewswire.com/23ef33094735e204421f6d8274b615e3","width":300,"height":80}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used to date","length":203,"tagName":"p"}]},{"val":[{"type":"text","content":"Topline data reported from the Phase II COVALENT-112 clinical trial of icovamenib in type 1 diabetes (“T1D”), supporting proposed mechanism of action","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"First patients dosed in the Phase II COVALENT-211 and COVALENT-212 clinical trials of icovamenib in type 2 diabetes (“T2D”); both trials are on track with topline 26-week data expected in the fourth quarter of 2026","length":214,"tagName":"p"}]},{"val":[{"type":"text","content":"The Phase I GLP-131 (BMF-650) obesity clinical trial is on track; initial 28-day weight reduction data expected in the second quarter of 2026","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash runway projected into the first quarter of 2027","length":52,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":759,"olType":false},{"type":"text","content":"SAN CARLOS, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 2026, and provided a business update.","length":295,"tagName":"p"},{"type":"text","content":"“Across our portfolio, we continue to execute with focus and discipline, with all of our key clini...